BioPharm America Digital, 20-23 September 2021.

BioPharm America attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts and it’s the perfect opportunity to engage with global life science partners. BioPharm America is where biotech industry partnerships get started. This year's event will be digital.

(April 2021)

Bio Europe, 25-28 October 2021.

BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. The international BIO-Europe 2021 gathering will be held digitally, standing tall in this time of insecurity, to execute on its pivotal role in bringing the global biopharma and investment leaders together to build partnerships that facilitate innovation and medical breakthroughs. Fulfilling its mission for the sector to connect the international life science community, BIO-Europe will once more allow you to connect and interact, remotely and safely, over four days, October 25-28, 2021.

(September 2021)

XVI International Pharma Licensing Symposium, Brighton UK, 22-24 June 2022.

The Pharmaceutical Licensing Group UK is hosting the XVI International Pharma Licensing Symposium (IPLS) and is bringing the event to Brighton from June 22-24, 2022. IPLS is a well-established international life science networking conference now in its 16th year. IPLS is a great opportunity for the healthcare deal-making community to come together to learn, discuss, network and partner.

(April 2021)

Xplico elected a Gazelle Company for the 4th year in a row

We are proud to announce that Xplico has been elected a Gazelle company for the 4^th year in a row.

The election is organized by the Danish financial newspaper Børsen, and the requirements to become a Gazelle company are tough. A Gazelle business is continuously growing and, as a minimum, doubles its revenue or gross profit over four fiscal years, while maintaining positive growth throughout the years.

It is quite impressive that we have been able to live up to this four years in a row and we express our gratitude to our customers because without their continuous support and trust this would not have been possible.

(October 2019)

The new Xplico Evaluator template is now released

Xplico proudly releases a new and enhanced version of Xplico Evaluator, our valuation tool, available for all our subscription customers.

Many things have been changed behind the scene, with only a few changes in the way the assumptions are entered. The new version can handle more advanced Deal Terms and it has more features as well as additional outputs.

(June 2019)

Publication of the Xplico Valuation Survey

(November 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Finn Nikolajsen, gives his point of view on the challenges of the ownership structures that the biotech companies and their investors face when they try to analyze the consequences of current and future funding rounds and exits.

Read the full article

(October 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, gives his point of view on the challenges that the Nordic life science companies face.

Read the full article

(August 2018)

Xplico Interview with Biotech & Money / LSX

In an interview with Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, explains how valuation is critical for strategic decision-making and points out to some of the common pitfalls companies encounter when using valuation models that are built in house.

Read the interview

(June 2018)